drugset
drugset / Trial / NCT02873767

A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers

NCT02873767 ↗

Phase 1 Completed 32 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupTriple-blindBasic science

Summary

This study is designed to evaluate the safety and tolerability of single ascending doses of UCB4019 administered by subcutaneous injection in healthy subjects.

Timeline

Start
2016-08
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject UCB4019 Unknown — Subcutaneous

Indications

No indication recorded.